Advertisement
U.S. markets closed

Bionomics Limited (BNOX)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
0.9950-0.0250 (-2.45%)
At close: 04:00PM EDT
0.9901 -0.00 (-0.49%)
After hours: 05:53PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close1.0200
Open1.0400
Bid0.7272 x 200
Ask1.2700 x 200
Day's Range0.9900 - 1.0499
52 Week Range0.8700 - 6.4100
Volume55,486
Avg. Volume192,454
Market Cap10.64M
Beta (5Y Monthly)-0.09
PE Ratio (TTM)N/A
EPS (TTM)-2.3900
Earnings DateApr 15, 2024 - Apr 23, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BNOX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Bionomics Limited - American De
    CYTK: Raising target price to $79.00CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $79.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • GlobeNewswire

    Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

    BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications. BNC210’s emerging safety and tolerability profile continues to support its differentiation over approved, available, and experimental psychoactive treatments. Bionomics will meet with the U.S. Food & Drug Administration (FDA) to discuss BNC210’s registrational program in PTSD by e

  • Simply Wall St.

    Bionomics First Half 2024 Earnings: AU$1.62 loss per share (vs AU$2.16 loss in 1H 2023)

    Bionomics ( NASDAQ:BNOX ) First Half 2024 Results Key Financial Results Net loss: AU$15.4m (loss narrowed by 5.2% from...

  • GlobeNewswire

    Bionomics to Present at the 2024 BIO CEO & Investor Conference

    ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be presenting at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 in New York, NY. Spyros Papapet